Production, quality control, biological evaluation and biodistribution modeling of Lutetium-177 maltolate as a viable bone pain palliative in skeletal metastasis

177Lu-maltolate (177Lu-MAL) was successfully developed which can be widely used in bone palliation therapy. At optimized conditions a radiochemical purity of about >99 % was obtained for 177Lu-MAL shown by ITLC (specific activity, 970-1,000 MBq/mmole). Biodistribution studies of 177Lu chloride and 177Lu-MAL were carried out in wild-type rats comparing the critical organ uptakes. Compartmental analysis was used to determine temporal biodistribution model of 177Lu-MAL in different organs. 177Lu-MAL is a possible therapeutic agent in human malignancies for the bone palliation therapy so the efficacy of the compound should be tested in various animal models. (author)